Lexaria Bioscience Corp. (LEXX)

Revenue by Segment

Financials in millions USD. Fiscal year is September - August.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019	Aug 31, 2018	Aug 31, 2017	Aug 31, 2016
Intellectual Property Licensing	696.00K	457.99K	146.80K	54.56K	334.97K
Intellectual Property Licensing Growth	51.97%	211.98%	169.06%	-83.71%	-
B2B Product	9.92K	6.29K	44.17K	113.44K	297.28K
B2B Product Growth	57.81%	-85.76%	-61.07%	-61.84%	96.05%
R & D	-	-	35.24K	54.80K	-
R & D Growth	-	-	-35.69%	-	-
Corporate	-	-	-	32.60K	90.49K
Corporate Growth	-	-	-	-63.97%	-
Total	705.92K	464.28K	226.21K	255.40K	722.74K
Total Growth	52.05%	105.24%	-11.43%	-64.66%	376.63%

Data Source: S&P Global Market Intelligence Last updated: Feb 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 23, 2026

Data Sources Report a data error